Nielsen enters agreement with Maruho for marketing rights to verruca vulgaris treatment
Click Here to Manage Email Alerts
Key takeaways:
- Nielsen’s potential earnings could exceed $100 million from this agreement with Maruho.
- Candin is a diagnostic skin test for the treatment of verruca vulgaris.
Nielsen BioSciences Inc. and Maruho Co. Ltd. have entered into a licensing agreement that grants Maruho an exclusive license to market Candin in Japan for the treatment of verruca vulgaris, according to a press release.
“The Nielsen team is excited to partner with Maruho in Japan, one of the larger dermatology markets in the world. Common warts affect approximately 10 percent of the global population and can cause more harm than people realize if left untreated,” David P. Burney, PhD, MBA, president and COO of Nielsen BioSciences, told Healio. “With no FDA-approved prescription treatment, there is significant patient need, and we are excited by the market opportunity and to help patients in need."
According to the release, Maruho will pay Nielsen a “substantial upfront payment” and will assume all costs associated with additional development and regulatory activities of Candin, a diagnostic skin test for the treatment of verruca vulgaris, known as common warts.
The deal also includes sales milestone payments based on Candin’s performance. According to the release, Nielsen’s earnings from this agreement could exceed $100 million.
As Candin is not currently approved by the FDA or Japan’s Pharmaceuticals and Medical Devices Agency, enrollment in a phase 3 trial is expected to start in the second half of 2023.
Read more about
Click Here to Manage Email Alerts